Check out your Company Bowl for anonymous work chats.
Together with L'Oréal, we are excited to announce the launch of the “My Skin & Hair Journey,” a multi-year study that will help researchers better understand the many complex factors that contribute to skin and hair health over time. The registry is now open for enrollment to US self-identifying women between the ages of 18-70 from various ethnicities and social backgrounds. “This program combines L’Oréal’s deep scientific knowledge of beauty with Verily’s comprehensive technology and clinical science capabilities. Through this multifaceted partnership, we aim to bring meaningful innovation to consumers and leverage data to deliver improved precision skin and hair health outcomes.” - Stephen Gillett, Verily CEO #PrecisionHealth #HealthTech #SkinHealth
Today we announced the appointment of Laura O'Donnell as our new General Counsel. She joins us from McKesson where she was SVP, Chief Compliance Officer. Welcome to Verily, Laura! Read the news in Bloomberg Law:
Today at Viva Technology, Amy Abernethy, our President of Product Development and Chief Medical Officer, and Nicolas HIERONIMUS, CEO of L'Oréal, talked on stage about our strategic partnership and additional research opportunities. Together we aim to understand the biological, clinical, and environmental factors that impact skin and hair health and beauty to deliver real and meaningful innovation. “What we found in L’Oreal is a partner with a shared passion for this opportunity to pioneer new research approaches, and a commitment to driving forward science to benefit consumers.” - Amy Abernethy
There is massive potential for using AI in the health and wellbeing industry. For startups looking to scale their business with the best of Google tools and resources, apply to the Google for Startups Growth Academy: AI for Health. Learn more 👇
Precision health starts with precision data. To make this a reality, we need to build a platform with the highest privacy and security standards, that can ingest high quality data across a depth of modalities. Hear more in the clip below from our CEO Stephen Gillett during his Fortune Brainstorm Health panel discussion about AI and how it can be applied to health care in a way that is trustworthy and safe. Watch the full recorded session below.
To transform health care and meet the challenges of today, we need a fundamental shift to make research, care, and risk protection work better. With our technology capabilities and clinical expertise, Verily has a unique opportunity to build solutions that can help. Our CEO Stephen Gillett and President of Product Development & Chief Medical Officer Amy Abernethy will share more about our new direction with Casey Ross of STAT during their session at STAT Breakthrough Summit on May 4 in San Francisco. Click the link to get virtual or in-person tickets.
Alphabet is #5! We're proud our parent company made the list, Top Companies 2023: The 50 Best Workplaces to Grow Your Career as ranked by LinkedIn. Want to join us? Check out our open roles below.
Our CEO Stephen Gillett takes the stage today at Fortune's Brainstorm Health conference to discuss AI’s impact on health and how to bolster cybersecurity. The increasing use of AI can accelerate health care by leaps and bounds, but we need to ensure data stays safe.
We continue to drive innovation in cancer research with AI. Together with Google Research, we’re excited to present an upcoming poster at the American Association for Cancer Research (AACR) Annual Meeting. This research describes the prediction of estrogen receptor RNA expression in breast cancer directly from standard (H&E stained) pathology images (poster #5357). Since H&E staining is a fast and inexpensive component of the standard tissue preparation in pathology, this approach has the potential to make gene expression profiling easier and more accessible. Read the abstract to learn more:
Exciting developments are on the horizon for inflammatory bowel disease (IBD) patients, thanks to our efforts with the Crohn's & Colitis Foundation to build a longitudinal, patient-centered registry. The data collected over time will help accelerate research and treatment. “Verily is working to develop a more holistic understanding of IBD, with help from those who know their conditions best – patients.” - Amy Abernethy, President, Product Development & Chief Medical Officer, Verily Learn about the research study and how to participate:
